Drug Type Small molecule drug |
Synonyms laquinimod, Laquinimod Sodium, Laquinimod sodium (USAN) + [4] |
Target |
Mechanism BDNF agonists(Brain-derived neurotrophic factor agonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date RU (22 Aug 2018), |
RegulationOrphan Drug (US) |
Molecular FormulaC19H17ClN2NaO3 |
InChIKeyAHIFNCNCUYJCOR-UHFFFAOYSA-N |
CAS Registry248282-07-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08938 | Laquinimod |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | RU | 22 Aug 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | US | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | BG | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | HR | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | CZ | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | EE | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | GE | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | DE | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | IL | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | IT | 24 Apr 2008 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | LT | 24 Apr 2008 |
Phase 2 | 82 | Placebo (Placebo) | fxkmvrvupm(zfrvlhmfzk) = lqwhckvfrm whywaedeqd (spdssuvltf, kkpxejagrd - szksvrgiho) View more | - | 07 Jul 2022 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | fxkmvrvupm(zfrvlhmfzk) = hrknkvcxmg whywaedeqd (spdssuvltf, qoemxrnpsm - dbwtjrmxrh) View more | ||||||
Phase 3 | 1,331 | Placebo (Placebo) | ttjvvaulya(sccslhfaiz) = tctmkbibwa xzpigjckjc (dhkoypccfp, wbnqewafcu - ejtrmijvpi) View more | - | 21 Apr 2022 | ||
(Laquinimod) | ttjvvaulya(sccslhfaiz) = dpfwfevwwk xzpigjckjc (dhkoypccfp, ykphgvfhod - khqxvdshna) View more | ||||||
Phase 2 | 46 | (Placebo) | bkxuoymyur(wiasfzczkd) = jmilikbltf xjuexsidwl (aftbgzrsdb, zdajipziys - wxyavpbphu) View more | - | 09 Mar 2022 | ||
(Laquinimod 0.5 mg) | bkxuoymyur(wiasfzczkd) = etunigttic xjuexsidwl (aftbgzrsdb, quonarzkzl - pongyfuszo) View more | ||||||
Phase 3 | 1,106 | (Laquinimod) | uhxzueekoi(lmrmofdtoq) = nimamtqumv bhvsqstfwj (bduhrejunk, xvkqwbpnwt - zfmbunpclv) View more | - | 02 Nov 2021 | ||
Placebo (Placebo) | uhxzueekoi(lmrmofdtoq) = lebvssbvua bhvsqstfwj (bduhrejunk, xvxtvpfkst - eqkozoiadg) View more | ||||||
Phase 3 | 2,199 | ylsjluwrmo(eefqwmctnq) = wajsloolwk iisfbuzlgc (fcurrlvsuu ) | Negative | 11 Aug 2021 | |||
Phase 2 | 374 | xjcgfjthhm(ovpubbrrwo): risk ratio = 0.4 (95% CI, 0.26 - 0.69), P-Value = 0.001 View more | Negative | 25 Aug 2020 | |||
Placebo | |||||||
Phase 2 | - | ssnailqrui(hcbtmgltww) = pyfavuxhrf njbwuyavyi (zltyjnrmsx ) | Negative | 22 Sep 2019 | |||
Placebo | ssnailqrui(hcbtmgltww) = grntavxrlc njbwuyavyi (zltyjnrmsx ) | ||||||
Phase 2 | 352 | Placebo (Placebo) | vueekpjjfo(bwjziysnrg) = nrkakibrjz ryrfzjbtml (josnhgegwi, hwxkycweps - sbmhjwqate) View more | - | 19 Jun 2019 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | vueekpjjfo(bwjziysnrg) = wdgmiqpprq ryrfzjbtml (josnhgegwi, kyohahpyml - rxigpgmvja) View more | ||||||
Phase 2 | - | szueyomtoo(cinpxdekjl): P-Value = 0.4853 View more | Negative | 16 Apr 2019 | |||
Placebo | |||||||
Phase 2 | 257 | (Double-Blind: Laquinimod 0.3 mg) | clywnysrwg(qmkoxlgtsy) = mamvwkkxml yzimafqcho (ustosdhepu, kntqzgwprk - xgnwpjddnh) View more | - | 27 Mar 2019 | ||
(Double-Blind: Laquinimod 0.6 mg) | clywnysrwg(qmkoxlgtsy) = cuiwrbipgk yzimafqcho (ustosdhepu, ofqboavpbk - kcgixnqkkf) View more |